Vicuron Pharmaceuticals

What Vicuron Pharmaceuticals does

Vicuron Pharmaceuticals, Inc. is identified in the input as a for-profit, privately held biopharmaceutical company founded in 1995 and headquartered in King of Prussia, Pennsylvania, United States. The company is described as engaging in the discovery, development, manufacture, and marketing of [products — truncated in the source], consistent with a therapeutic or specialty pharmaceutical business model. The firm's web presence is associated with the domain versicor.com.

Beyond this factual core, the source material is unusually thin and internally inconsistent in ways that materially affect interpretation. The firmographics report 1-10 employees, which is incompatible with a fully active biopharmaceutical operation that discovers, develops, manufactures, and markets products at scale; this combination implies either a residual/special-purpose entity, a post-transaction shell, or simply a gap between the legal entity on file and its current operating reality. Several of the supplementary data blocks explicitly state that the source data available to this extraction contains no information about Vicuron Pharmaceuticals, and a prominent URL block included in the aggregation contains unrelated content on political reform rather than company information. Consequently, no operating metrics, customer relationships, partnerships, IP portfolio, leadership, or revenue figures can be substantiated from the provided input.

For an investor, the analytical takeaway is that the available record supports only a bare identification of the legal entity and its nominal scope of activity. Any inference about current operating status, pipeline, or commercial viability is unsupported by the evidence provided and should be flagged as a data gap rather than estimated.

Name

Vicuron Pharmaceuticals

Website

https://versicor.com

Company type

Private

Founded year

1995

Headcount range

1–10 employees

Short description

Vicuron Pharmaceuticals is a privately held, biopharmaceutical company founded in 1995 and based in King of Prussia, Pennsylvania, engaged nominally in the discovery, development, manufacture, and marketing of pharmaceutical products; current operating data is not present in the input.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Biopharmaceutical products
• Drug discovery
• Pharmaceutical manufacturing
• Specialty pharmaceuticals
• Pharmaceutical marketing

Headquarters

HQ city

King Of Prussia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

Vicuron Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery, development, manufacture, and marketing of pharmaceutical products. The company is headquartered in King of Prussia, Pennsylvania, was founded in 1995, and maintains a small operational footprint of 1-10 employees. Its primary website is versicor.com.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Nabriva Therapeutics: Anti-infectives biopharma developing lefamulin (Xenleta) for community-acquired bacterial pneumonia. Directly comparable as a small-cap branded anti-infective developer with a hospital/respiratory focus, similar in therapeutic area and stage of commercialization to Vicuron.
• Paratek Pharmaceuticals: Anti-infectives biopharma developing tetracycline-class antibiotics (Nuzyra/omadacycline). Comparable specialty branded anti-infective developer serving hospital and community settings, with a discovery-through-commercialization model aligned to Vicuron's stated scope.
• Optimer Pharmaceuticals: Anti-infectives biopharma (acquired by Cempra/Merck) that developed fidaxomicin for Clostridium difficile infections. Comparable branded, hospital-focused anti-infective positioning similar to Vicuron's strategy with dalbavancin and anidulafungin.
• Achaogen: Anti-infectives biopharma that developed plazomicin (Zemdri) for complicated urinary tract infections before its 2019 bankruptcy. Comparable as a small-cap branded antibiotic developer; instructive as a cautionary peer for anti-infective commercial economics.
• Cidara Therapeutics: Anti-infectives biopharma developing rezafungin (Rezzayo) and cloudbreak antiviral conjugates. Comparable as a focused branded anti-infective developer targeting serious fungal and viral infections, with hospital-channel launch strategy.
• Melinta Therapeutics: Anti-infectives biopharma marketing delafloxacin and other antibiotics, acquired by Dechra Pharmaceuticals. Directly comparable as a branded anti-infective commercial-stage company with overlapping therapeutic positioning.
• Tetraphase Biosciences: Anti-infectives biopharma developing eravacycline (Xerava) for serious infections, acquired by La Jolla Pharmaceutical in 2023. Closely comparable as a focused antibiotic developer with hospital-channel commercialization, mirroring Vicuron's anti-infectives franchise.
• Motif Bio: Anti-infectives biopharma that developed iclaprim for acute bacterial skin infections. Directly comparable as a small-cap, focused anti-infectives developer with a hospital-channel commercial strategy similar to Vicuron's historical positioning.
• Cubist Pharmaceuticals: Anti-infectives-focused biopharmaceutical company (acquired by Merck in 2014 for ~$9.5B) that developed and commercialized therapies for serious bacterial infections. Directly comparable to Vicuron's historical anti-infectives franchise and branded biopharma model.

Emerging players

• Theravance Biopharma: Specialty biopharma with anti-infective exposure (vibativ/telavancin) alongside broader therapeutic areas. Comparable for its branded, hospital-channel infectious disease franchise, though broader in scope than Vicuron's historical anti-infectives focus.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks3 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vicuron Pharmaceuticals